Merck & Co., Inc. (NYSE:MRK) Sets New 52-Week High – Here’s What Happened

Merck & Co., Inc. (NYSE:MRK)’s share price hit a new 52-week high during trading on Friday . The company traded as high as $131.59 and last traded at $131.1330, with a volume of 1744882 shares. The stock had previously closed at $127.63.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approval of LIPFENDRA gives Merck its first oral PCSK9 inhibitor, opening a new revenue stream in cardiovascular care and strengthening its non-oncology portfolio. Reuters article on FDA approval
• Positive Sentiment: Analysts highlighted continued oncology pipeline progress, including FDA acceptance of multiple regulatory filings and Merck’s broader effort to offset the eventual 2028 Keytruda patent cliff. Seeking Alpha article on pipeline expansion
• Neutral Sentiment: Coverage also noted that Lipfendra’s launch is expected soon and that the drug could become a major product over time, though sales will depend on uptake, pricing, and competition from existing cholesterol therapies. Zacks article on Lipfendra launch
• Neutral Sentiment: There was also a rumor that Merck may be in a takeover battle for genomics company Personalis, but this appears speculative and is not confirmed. Yahoo Finance article on Personalis rumor

Wall Street Analyst Weigh In

MRK has been the topic of several recent research reports. Scotiabank increased their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a report on Tuesday, June 30th. Bank of America lifted their price objective on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Wells Fargo & Company boosted their price objective on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, July 8th. Guggenheim increased their target price on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $120.00 target price on shares of Merck & Co., Inc. in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $133.94.

Merck & Co., Inc. Price Performance

The stock has a market capitalization of $314.83 billion, a PE ratio of 35.91, a price-to-earnings-growth ratio of 4.39 and a beta of 0.19. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The stock’s 50 day moving average price is $120.11 and its 200-day moving average price is $116.94.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter last year, the firm posted $2.22 EPS. The firm’s revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities analysts forecast that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th were paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is currently 95.77%.

Institutional Trading of Merck & Co., Inc.

Several institutional investors and hedge funds have recently modified their holdings of MRK. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. in the 4th quarter worth $25,000. Abound Financial LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter worth $26,000. Prosperity Bancshares Inc purchased a new position in shares of Merck & Co., Inc. during the fourth quarter valued at $26,000. High Note Wealth LLC increased its stake in shares of Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. bought a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at about $31,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.